144 related articles for article (PubMed ID: 11895205)
1. I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial.
Wallner K; Merrick G; True L; Cavanagh W; Simpson C; Butler W
Cancer J; 2002; 8(1):67-73. PubMed ID: 11895205
[TBL] [Abstract][Full Text] [Related]
2. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.
Herstein A; Wallner K; Merrick G; Mitsuyama H; Armstrong J; True L; Cavanagh W; Butler W
Cancer J; 2005; 11(5):385-9. PubMed ID: 16259869
[TBL] [Abstract][Full Text] [Related]
3. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
4. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials.
Ghaly M; Wallner K; Merrick G; True L; Sutlief S; Cavanagh W; Butler W
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1288-93. PubMed ID: 12654439
[TBL] [Abstract][Full Text] [Related]
5. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
Gelblum DY; Potters L; Ashley R; Waldbaum R; Wang XH; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):59-67. PubMed ID: 10477007
[TBL] [Abstract][Full Text] [Related]
6. Urinary morbidity with a modified peripheral loading technique of transperineal (125)i prostate implantation.
Brown D; Colonias A; Miller R; Benoit R; Cohen J; Arshoun Y; Galloway M; Karlovits S; Wu A; Johnson M; Quinn A; Kalnicki S
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):353-60. PubMed ID: 10802359
[TBL] [Abstract][Full Text] [Related]
7. Clinical correlates of high intraprostatic brachytherapy dose volumes.
Jones S; Wallner K; Merrick G; Corriveau J; Sutlief S; True L; Butler W
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):328-33. PubMed ID: 12023136
[TBL] [Abstract][Full Text] [Related]
8. Rectal function following prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Galbreath RW; Blatt H; Lief JH
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):667-74. PubMed ID: 11020562
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
[TBL] [Abstract][Full Text] [Related]
10. Urinary symptom flare following I-125 prostate brachytherapy.
Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
[TBL] [Abstract][Full Text] [Related]
11. Iodine 125 versus palladium 103 implants for prostate cancer: clinical outcomes and complications.
Peschel RE; Colberg JW; Chen Z; Nath R; Wilson LD
Cancer J; 2004; 10(3):170-4. PubMed ID: 15285926
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
13. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
Stone NN; Stock RG
Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
[TBL] [Abstract][Full Text] [Related]
14. Epididymitis after prostate brachytherapy.
Hoffelt SC; Wallner K; Merrick G
Urology; 2004 Feb; 63(2):293-6. PubMed ID: 14972474
[TBL] [Abstract][Full Text] [Related]
15. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
16. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
17. Temporal resolution of urinary morbidity following prostate brachytherapy.
Merrick GS; Butler WM; Lief JH; Dorsey AT
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):121-8. PubMed ID: 10758313
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study.
Blanchard P; Pugh TJ; Swanson DA; Mahmood U; Chen HC; Wang X; Graber WJ; Kudchadker RJ; Bruno T; Feeley T; Frank SJ
Brachytherapy; 2018; 17(2):265-276. PubMed ID: 29269207
[TBL] [Abstract][Full Text] [Related]
19. Permanent prostate brachytherapy using high V150.
Serrano NA; Pham HT; Narayanan S; Badiozamani KR
Pract Radiat Oncol; 2015; 5(3):e201-e206. PubMed ID: 25413406
[TBL] [Abstract][Full Text] [Related]
20. The time gap between Pd-103 prostate brachytherapy and supplemental beam radiation does not impact on rectal morbidity or likelihood of cure.
Bittner N; Wallner K; Merrick G; Orio P; Nurani R; True L
Am J Clin Oncol; 2008 Jun; 31(3):231-6. PubMed ID: 18525300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]